Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?

The Chinese University of Hong Kong

Status: Terminated

Conditions: Non-Cardiac Chest Pain

Treatments: Drug: Baclofen, Diltiazem

Study type: Interventional

Funder types: Other

Identifiers

NCT00164801

NPB study

Details and patient eligibility

About

The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese.We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.

Enrollment: 60 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Consecutive patients with monthly angina-like chest pain and negative coronary angiogram or scintigraphy
• Age between 18-70
• Gastroesophageal reflux disease
• Psychiatric illness
• Cerebrovascular accident
• Active peptic ulceration
• Heart failure or cardiac bradyarrhythmia
• Epilepsy
• Pregnancy or lactating female
• Previous hypersensitivity to muscle relaxant

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind